Aprea reports Phase 1 data for WEE1 inhibitor APR-1051
Aprea announced interim Phase 1 results showing partial responses in uterine cancer patients, supporting continued dose optimization and the planned expansion into specific breast and ovarian cancer cohorts.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed